RVTYNYSELaboratory Analytical InstrumentsFiscal year ends December 29
REVVITY, INC.
Financials through Q2 FY2026, quarter ended Jul 5, 2026Last filing: 10-Q on Aug 11, 2026
$150.94−1.70 (-1.11%)
Close on Oct 19, 2026
- Market cap
- $16.85B
- P/E (TTM)
- 71.9
- Dividend yield
- 0.19%
REVVITY, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences [Member] | $1.43B | $1.40B | $1.46B | $1.29B | $895.87M | – | – | – | – | – | 50.1% | +2.3% |
| Diagnostics [Member] | $1.42B | $1.36B | $1.29B | $2.02B | $2.93B | $2.07B | $1.14B | $1.08B | $678.52M | $602.53M | 49.9% | +5.1% |
| Discovery & Analytical Solutions [Member] | – | – | – | $1.29B | $895.87M | $596.29M | $1.75B | $1.69B | $1.58B | $1.51B | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics [Member] | – | – | – | – | $1.22B | $874.21M | $189.33M | $153.20M | $146.86M | $148.00M | – |
| Corporate [Member] | – | – | – | – | -$77.36M | -$79.10M | -$65.69M | -$59.79M | -$56.51M | -$49.92M | – |
| Discovery & Analytical Solutions [Member] | – | – | – | – | $189.80M | $183.47M | $238.33M | $230.48M | $205.26M | $196.51M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $2.39B | $2.34B | $2.42B | $2.63B | $2.74B | $2.28B | $2.02B | $1.94B | $1.48B | $1.40B | 83.7% | +2.2% |
| Service [Member] | $466.07M | $416.82M | $334.68M | $677.24M | $1.09B | $382.38M | $866.63M | $842.50M | $779.57M | $718.62M | 16.3% | +11.8% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total international [Member] | $1.73B | $1.66B | $1.63B | $1.77B | $2.15B | $1.74B | $1.91B | $1.87B | $1.42B | $1.27B | 60.6% | +4.4% |
| Americas [Member] | $1.26B | $1.22B | $1.22B | $1.66B | $1.81B | $1.04B | $1.12B | $1.07B | – | – | 44.0% | +2.7% |
| United States | $1.13B | $1.10B | $1.12B | $1.55B | $1.68B | $921.57M | $974.19M | $906.40M | $837.02M | $842.36M | 39.4% | +2.6% |
| Other International [Member] | $1.00B | $931.71M | $859.90M | $1.15B | $1.34B | $1.11B | $1.26B | $671.61M | $569.44M | $528.76M | 35.0% | +7.4% |
| Europe [Member] | $824.98M | $742.61M | $747.02M | $831.81M | $1.22B | $1.02B | $787.38M | $778.09M | – | – | 28.9% | +11.1% |
| Asia [Member] | $775.11M | $789.33M | $787.94M | $817.37M | $804.33M | $604.27M | $977.50M | $934.78M | – | – | 27.1% | -1.8% |
| China | $425.06M | $450.01M | $454.43M | $476.37M | $449.59M | $305.66M | $581.69M | $559.87M | $374.93M | $336.73M | 14.9% | -5.5% |
| Germany | $177.66M | $162.58M | $193.17M | – | – | $200.29M | $146.58M | $142.41M | $91.67M | $89.84M | 6.2% | +9.3% |
| United Kingdom | $126.85M | $112.88M | $125.42M | $136.02M | $357.91M | $323.84M | $70.70M | $72.12M | $65.16M | $65.90M | 4.4% | +12.4% |
| France | – | – | – | – | – | $148.90M | $96.99M | $97.99M | $80.15M | $71.10M | – | – |
| Italy | – | – | – | – | – | $163.06M | $101.46M | $95.91M | $77.48M | $70.95M | – | – |
| Japan | – | – | – | – | – | $88.47M | $82.48M | $79.24M | $76.32M | $65.98M | – | – |
| India | – | – | – | – | – | $103.79M | $97.42M | $92.33M | $84.81M | $43.89M | – | – |
| South Korea | – | – | – | – | – | $114.85M | $71.07M | $60.13M | – | – | – | – |
From the segment and revenue-disaggregation notes of Revvity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.